Ultivue

Market position

At the time of the merger, Vizgen and Ultivue were described as the two largest private companies in the spatial biology segment, with Ultivue characterized as a leader in multiplex proteomic profiling and Vizgen in single-cell spatial genomics. The merger was framed as part of a broader consolidation wave in spatial biology that also included Bruker's acquisition of NanoString Technologies out of bankruptcy for $392.6 million, Bruker's build-out of Canopy Biosciences, and Bio-Techne's acquisition of Lunaphore. The combined company aims to increase its presence in clinical laboratory settings while continuing to serve research institutions and biopharma.

Reported differentiators include the proprietary InSituPlex chemistry using DNA-barcoded antibodies with direct linear amplification for up to 12 simultaneous biomarkers with quantitatively consistent signal; the ability to combine fluorescent multiplex immunofluorescence with conventional H&E morphological staining on the same tissue section; assay development reported as 70% faster than conventional approaches through pre-optimized ready-to-use kits; an end-to-end service model spanning custom assay design, validated panels, proof-of-concept studies and image analysis; AI-based analysis via STARVUE and an Aignostics partnership with GCP-compliant options; and CLIA-accredited laboratory infrastructure. After the merger, the combined company positions the pairing of spatial proteomics and spatial transcriptomics workflows on a single vendor platform as its principal distinction.

Technology

InSituPlex multiplex immunofluorescence uses DNA-barcoded antibodies with direct linear amplification to detect up to 12 biomarkers in one FFPE tissue section, and can be combined with H&E staining on the same slide; OmniVUE pre-configured panels and U-VUE custom panels sit on top of this chemistry, with the STARVUE AI image data science pipeline providing quantitative analysis. The merged Vizgen portfolio adds MERFISH (Multiplexed Error-Robust Fluorescence in situ Hybridization) spatial transcriptomics, delivered as MERFISH 2.0 chemistry on the MERSCOPE and MERSCOPE Ultra platforms, mapping up to 1,000 RNA targets at single-cell, subcellular resolution across up to 3 cm² of tissue, including lower-quality FFPE samples.

Go-to-market

Direct sales and partnerships within the life sciences sector, supplemented by a consultative service model and distribution partnerships with biotech firms. Marketing runs through scientific conferences (for example poster presentations at the AACR Annual Meeting in April 2025 and the HCA 2026 meeting), peer-reviewed publications and preprints referencing the platforms, application and technical notes, datasets, and customer testimonials from academic investigators and CROs such as HistologiX.

Academic and research institutions, biotechnology firms, pharmaceutical companies and CROs working in oncology, immunology and neuroscience, including translational research and clinical trial biomarker programs; the merged company also targets clinical laboratory settings.

Geography

Headquartered in Cambridge, Massachusetts, US. Secondary sources describe operations spanning North America, Europe and Asia, with products used primarily by customers in North America and Europe. Vizgen, the merged entity, reports MERSCOPE platforms installed globally and, per Preqin, plans to explore expansion into new geographic regions.

History

Founded in 2015 in Cambridge, Massachusetts, Ultivue delivered its first customer project in 2018 and saw peer-reviewed customer publications in 2019. It raised a $5M Series A in 2015, a Series B in 2018, a Series C in 2019 led by Northpond Ventures, and a $50M Series D in April 2021; the same year its services laboratory achieved CLIA certification. By 2023 it had global operations and had launched OmniVUE panels and an AI ecosystem for spatial image analysis, including an Aignostics partnership. Rob Carson joined as CEO in 2023 (described in an October 2024 article as having served as CEO and president 'since last year') after executive roles at Medtronic, Waters and Harbinger Health. In October 2024 Ultivue merged into Vizgen, Inc., with the combined company operating under the Vizgen name and Carson as president and CEO; Preqin lists Ultivue's stage as 'Merged'. The ultivue.com domain now serves Vizgen content, and Carson indicated the Ultivue name and sub-brands such as STARVUE and OmniVUE would migrate under the Vizgen umbrella over time rather than be retired immediately.

Risks & controversies

Sources report materially inconsistent financial figures: one aggregator lists $97.0M raised across four rounds while its own narrative cites 'over $120 million' and different Series B/C amounts ($14M and $37M) than its round table ($20M and $22M); Preqin lists a 2024 Series A of $12.00mn and a valuation of $33.82mn and names Jacques Corriveau as CEO, conflicting with other sources naming Rob Carson. The same aggregator lists an implausible employee count of 10,000+. The broader spatial biology sector is described as consolidating amid financial distress and litigation, including NanoString's Chapter 11 filing after a $31 million patent-infringement jury award to 10x Genomics.